Article Per Year (5 Year)
p-Index From 2021 - 2026
1.704
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal Molecular and Cellular Biomedical Sciences (MCBS)
Nurrani Mustika Dewi, Nurrani Mustika
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 14 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 14 Documents
Search

 1   2 
Roles of Mesenchymal Stem Cell-derived Extracellular Vesicles in Cancer: Development and Target Therapy Meiliana, Anna; Dewi, Nurrani Mustika; Wijaya, Andi
The Indonesian Biomedical Journal Vol 17, No 1 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i1.3408

Abstract

Extracellular vesicles (EVs) are membrane structures that enclose proteins, lipids, RNAs, metabolites, growth factors, and cytokines. EVs derived from mesenchymal stem cells (MSCs) can either stimulate or inhibit tumor growth in various malignancies through paracrine signaling. Tumor-associated MSCs (TA-MSCs), often described as "wounds that never heal," actively participate in the development, propagation, and metastasis of tumors, impacting the immunological state of the tumor microenvironment. For instance, TA-MSCs can alter immune cell recruitment and cytokine production, leading to a pro-tumorigenic environment. Consequently, both the tumor and its microenvironment undergo functional alterations, the cargo of exosomes is modified, and an abnormal tumor-associated MSC phenotype is acquired. MSC-EVs contain exosome microRNA with both tumor-inhibitory and tumor-supportive effects. For example, MSC-EVs have been shown to deliver tumor-suppressive microRNAs that inhibit cancer cell proliferation and induce apoptosis. This review outlines the criteria for the modification, isolation, and characterization of exosomes, as well as their application in cancer, providing insights for clinical use. By understanding these mechanisms, we can better harness MSC-EVs for therapeutic purposes.Keywords: mesenchymal stem cell, extracellular vesicle, exosome, cancer therapy, drug delivery
Sarcopenic Obesity: The Underlying Molecular Pathophysiology and Prospect Therapies Meiliana, Anna; Dewi, Nurrani Mustika; Defi, Irma Ruslina; Rosdianto, Aziiz Mardanarian; Qiantori, Adziqa Ammara; Wijaya, Andi
The Indonesian Biomedical Journal Vol 16, No 4 (2024)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v16i4.3176

Abstract

BACKGROUND: Age contributes to body composition alteration, rises a common disorder in elderly known as sarcopenic obesity (SO), which is characterized by the combination of obesity (excess fat mass) and sarcopenia (reduced skeletal muscle mass) clinical form and function.CONTENT: The primary cause of SO is insulin resistance. Glucose transporter 4 (GLUT4) dysfunction results in impaired fatty acids oxidation. Decreased muscle mass results in lower mitochondria number and volume. Both will increase oxidative stress. Together with altered myokines in SO, oxidative stress was promoted and lead to higher M1 macrophages and failure in autophagy. The pro-inflammatory condition and dysbiosis links SO to a variety of cardiometabolic conditions, including non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. The mortality, comorbidities, cardiometabolic diseases, and disability or impairment of SO is higher compare to obesity or sarcopenia alone. Some treatments have been developed for SO including adequate dietary intake, vitamin D and antioxidant supplementation, and exercises.SUMMARY: SO is more prevalent among the elderly and has a significant negative impact on their quality of life. Therefore, maintaining muscle mass and strength as well as preventing obesity should be the key goals of initiatives to support healthy aging.KEYWORDS: aging, body composition, obesity, sarcopenia, skeletal muscle, metabolic syndrome
Serum β-amyloid 1–42 Levels as Alternative Non-invasive Screening Biomarker for Alzheimer’s Disease and Vascular Dementia in Indonesian Elderly Population Putri, Indah Aprianti; Darusman, Huda Shalahuddin; Hamdan, Muhammad; Prawiroharjo, Pukovisa; Utomo, Budi; Nugraha, Jusak; Kusuma, Yohanna; Dewi, Nurrani Mustika; Sandra, Ferry
The Indonesian Biomedical Journal Vol 17, No 6 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i6.3869

Abstract

BACKGROUND: Alzheimer’s disease (AD) and vascular dementia (VaD) impose a substantial public health burden in Indonesia; however, accessible blood-based biomarkers for early screening remain limited. Although cerebrospinal fluid β-amyloid 1–42 is an established biomarker, its invasive nature restricts its use for population-level screening. Therefore, it is necessary to have locally-produced serum β-amyloid 1–42 ELISA kit that is specifically designed for Indonesian elderly population. In this study, a locally-produced β-amyloid 1–42 ELISA kit was validated and used for the screening of AD, VaD and mild cognitive impairment (MCI) Indonesian population.METHODS: A cross-sectional study including 166 subjects: 31 AD, 34 VaD, 34 MCI patients, and 67 cognitively normal controls was conducted. All participants underwent cognitive assessments including Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment-Indonesian version (MoCA-Ina), as well as brain magnetic resonance imaging (MRI) 3-Tesla for the assessment of medial temporal atrophy/white matter changes. Fasting venous blood sampling was taken from each subjects for the measurement of serum β-amyloid 1-42 measurement using locally-produced ELISA kit.RESULTS: Median serum β-amyloid 1–42 levels were 11.03, 10.99, and 10.99 pg/mL for the AD, VaD, and MCI subjects, respectively. The β-amyloid 1–42 levels were correlated with MMSE scores in all group (AD: r=−0.455, p=0.010; VaD: r=−0.419, p=0.014; MCI: r=−0.412, p=0.015). The validity analysis of the locally-produced serum β-amyloid 1–42 ELISA kit, showed sensitivity of 94.12% (95% CI: 87.3–97.9), specificity of 80.36% (95% CI: 72.4–86.8), and diagnostic accuracy of 83.56% (95% CI: 77.2–88.5).CONCLUSION: Serum β-amyloid 1–42 levels are lower in AD and VaD subjects compared to MCI and control subjects. Serum β-amyloid 1-42 is inversely correlated with cognitive function across all groups based on MMSE score. Additionally, the locally-produced β-amyloid 1-42 ELISA kit demonstrated sensitivity of 94.12% and specificity of 80.36%, meeting Global CEO Initiative Consensus for pre-screening tools, supporting its potential as a scalable, non-invasive screening biomarker in Indonesian primary care settings.KEYWORDS: G-banding karyotyping, next generation sequencing, non-invasive prenatal testing
Sarcopenia as a Risk of Modern Obesity Treatments: A Review of Molecular Mechanisms and Prevention Strategies Meiliana, Anna; Dewi, Nurrani Mustika; Wijaya, Andi
The Indonesian Biomedical Journal Vol 17, No 6 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i6.3583

Abstract

While lifestyle interventions and metabolic surgery for obesity have limitations, incretin-based therapies have emerged as highly effective treatments. However, their success is shadowed by a significant risk, which is the loss of lean skeletal muscle, which can induce sarcopenia or sarcopenic obesity. Given the vital role of skeletal muscle in overall health, it is crucial to accurately assess this condition using standard clinical measures. Exercise stands as the most potent countermeasure, acting as medicine to preserve muscle and improve metabolic health. Its benefits are driven by a complex interplay of mechanisms. Different exercise types trigger the release of myokines and exerkines, while a regulated inflammatory response is essential for muscle adaptation and regeneration. This regenerative process, involving muscle stem cells, is further governed by epigenetic factors and critical molecular pathways like Akt and insulin that maintain muscle mass. To optimize these effects, adequate protein intake and targeted nutritional strategies are essential, supporting muscle protein synthesis and recovery. Supplementation, particularly with leucine-rich amino acids or vitamin D, may further enhance anabolic responses, especially in older adults. Clinical monitoring of muscle mass, strength, and nutritional biomarkers should be integrated into obesity care to detect early signs of sarcopenia and guide individualized interventions. Therefore, it is imperative that obesity therapy evolves to prevent muscle loss. This review highlights the risk of therapy-induced sarcopenia from modern obesity treatments, emphasizing the need for integrated prevention strategies, centered on exercise, and reinforced by nutrition, supplementation, and clinical monitoring to ensure healthy, sustainable weight loss.KEYWORDS: sarcopenia, skeletal muscle, inflammation, obesity, incretin
Co-Authors ANDI WIJAYA Angliana Chouw, Angliana Anna Meiliana Budi Utomo Ferry Sandra Huda Shalahudin Darusman Irma Ruslina Defi Jusak Nugraha Kusuma, Yohanna Muhammad Hamdan Pukovisa Prawiroharjo, Pukovisa Putri, Indah Aprianti Qiantori, Adziqa Ammara Rina Triana, Rina Rosdianto, Aziiz Mardanarian Siska Darmayanti, Siska